34146-68-4

Usage

Uses

Used in Pharmaceutical Industry:
8-methoxy-1,2,3,4-tetrahydroisoquinoline is used as a pharmacological agent for its potential role in the treatment of neurodegenerative disorders such as Parkinson's disease. Its activity as a dopamine D2 receptor agonist makes it a candidate for managing motor symptoms associated with these conditions.
Used in Neuroprotective Agents Development:
In the field of neuroprotection, 8-methoxy-1,2,3,4-tetrahydroisoquinoline is utilized for its antioxidant properties, which may help in safeguarding neurons from oxidative stress-induced damage, a common pathological feature in various neurodegenerative diseases.
Used in Research and Development:
8-methoxy-1,2,3,4-tetrahydroisoquinoline serves as a subject of interest in scientific research for exploring its potential as a lead compound in the development of new therapeutic agents targeting central nervous system disorders. Its multifaceted pharmacological profile, including receptor agonism and neuroprotection, makes it a valuable asset in drug discovery and design processes.

InChI:InChI=1/C10H13NO/c1-12-10-4-2-3-8-5-6-11-7-9(8)10/h2-4,11H,5-7H2,1H3

Upstream product

• 29969-40-2 2-formyl-1,2,3,4-tetrahydro-8-methoxyisoquinoline 
• 15184-99-3 N,N-dimethyl-3-methoxybenzylamine 
• 81625-31-2 2-(ethoxycarbonyl)-3-methoxyphenylacetonitrile 
• 81625-32-3 2-(2-Amino-ethyl)-6-methoxy-benzoic acid ethyl ester 
• 50-00-0 formaldehyd 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 108-95-2 phenol 
• 34985-41-6 7-methoxy-indan-1-one 
• 6968-35-0 7-hydroxy-indan-1-one 
• 24552-27-0 3-chloropropionic acid phenyl ester 
• 33543-63-4 ethyl-N-<2-(3-methoxyphenyl)ethyl>-carbamate 
• 110339-52-1 C₁₀H₁₃NO 
• 81625-30-1 2-(ethoxycarbonyl)-3-methoxybenzyl chloride 
• 81625-29-8 N,N-dimethyl-2-(ethoxycarbonyl)-3-methoxybenzylamine 

Downstream Products

• 1723-70-2 8-methoxyisoquinoline 
• 24693-44-5 8-methoxy-3,4-dihydroisoquinoline 
• 81625-39-0 2-(4-phenylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-37-8 2-(4-tert-butylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 32999-37-4 1,2,3,4-tetrahydroisoquinoline-8-ol 
• 464900-21-8 8-hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 81625-35-6 1-hydroxy-2-benzoyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-40-3 1-<4-(benzyloxy)benzyl>-2-(4-tert-butylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-41-4 1-<4-(benzyloxy)benzyl>-2-(4-phenylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-20-9 1-(3,4-dimethoxybenzyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-22-1 1-<4-(benzyloxy)benzyl>-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 508235-82-3 5-(3,4-Dimethoxybenzylamino)-2-(2-furyl)-8-(8-methoxy-1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine 
• 73903-30-7 8-Methoxy-2-methyl-1,2,3,4-tetrahydroisochinolin 
• 81625-36-7 2-benzoyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline 

Relevant academic research and scientific papers

Benzimidazole compound, preparation method thereof and application of the benzimidazole compound in preparation of ferroptosis inhibitor

The invention discloses a benzimidazole compound, a preparation method thereof and application of the benzimidazole compound in preparation of a ferroptosis inhibitor. The benzimidazole compound has a structure as shown in a formula (I) or a formula (II)

A class of GPR40 agonist compounds with amide structure, and uses thereof

The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.

UREA PEPTOID BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present invention provides a urea peptidomimetic boronic compound and pharmaceutical compositions thereof, their preparative methods and uses. The compounds are represented by the following formula (I).

Tyrosine Kinase Inhibitor And Uses Thereof

Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

Structure-Based Design and Discovery of New M2 Receptor Agonists

Muscarinic receptor agonists are characterized by apparently strict restraints on their tertiary or quaternary amine and their distance to an ester or related center. On the basis of the active state crystal structure of the muscarinic M2 receptor in complex with iperoxo, we explored potential agonists that lacked the highly conserved functionalities of previously known ligands. Using structure-guided pharmacophore design followed by docking, we found two agonists (compounds 3 and 17), out of 19 docked and synthesized compounds, that fit the receptor well and were predicted to form a hydrogen-bond conserved among known agonists. Structural optimization led to compound 28, which was 4-fold more potent than its parent 3. Fortified by the discovery of this new scaffold, we sought a broader range of chemotypes by docking 2.2 million fragments, which revealed another three micromolar agonists unrelated either to 28 or known muscarinics. Even pockets as tightly defined and as deeply studied as that of the muscarinic reveal opportunities for the structure-based design and the discovery of new chemotypes.

Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter

The synthesis and structure-activity relationship of a new class of indole derivatives with low-nanomolar affinity for the SERT and high selectivity versus the 5-HT1A receptor were recently reported. Based on their chemical structure, four new indolylpropylamine derivatives which contain atoms to afford future labeling with PET isotopes, were synthesized and evaluated as SERT ligands. The chemistry of these novel derivatives, their biological evaluation, the general method of preparing the precursor indole for labeling, and the C-11 labeling of the most promising indole derivative, are described herein.

SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure

Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5-tetrahydro-1H-2-benzazepine and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives.

Synthesis and SAR of novel histamine H3 receptor antagonists

The synthesis and biological evaluation of novel tetrahydroisoquinoline, tetrahydroquinoline, and tetrahydroazepine antagonists of the human and rat H3 receptors are described. The substitution around these rings as well as the nature of the substituent on nitrogen is explored. Several compounds with high affinity and selectivity for the human and rat H3 receptors are reported.

Studies towards the next generation of antidepressants. Part 1: Indolylcyclohexylamines as potent serotonin reuptake inhibitors

A series of indolylcyclohexylamines possessing potent and selective serotonin reuptake inhibition is reported. The most interesting compounds proved to have subnanomolar 5-HT transporter activity, and exhibited moderate 5-HT1A affinity.

A synthesis of mono- and dimethoxy-1,2,3,4-tetrahydroisoquinolines via Pummerer reaction: Effects of methoxyl groups on intramolecular cyclization

A synthesis of 1,2,3,4-tetrahydroisoquinolines (TIQs) (23) with one and two methoxyl groups at various positions of the benzene ring was achieved via the intramolecular cyclization of N-(aryl)methyl-2- (phenylsulfinyl)ethylamines (9) using the Pummerer reaction as a key step. The reaction was carried out by using trifluoroacetic anhydride (TFAA) (method A) or TFAA-BF3 · Et2O (method B). The cyclization to 4-SPhTIQs (11) proceeded effectively when the reaction center at the benzene ring was electronically activated by a methoxyl group. In the reaction of the sulfoxide (9e) having two OMe groups at ortho- and para-positions a different cyclization reaction leading to a benzothiazepine (12) was observed, indicating that the high nucleophilicity of the benzene ring caused the unexpected reaction prior to the cyclization to 4-SPhTIQ (11e). The route starting from methoxylated benzaldehydes (5) was proved to provide an efficient and convenient method of TIQ synthesis which should be complementary to the well known Pictet-Spengler method.